Literature DB >> 19914249

Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimer's disease.

Francisco J Barrantes1, Virginia Borroni, Sofía Vallés.   

Abstract

Alzheimer's disease (AD) is one of the most devastating diseases of the central nervous system (CNS). It is characterized by two neuropathological findings: amyloid plaques and neurofibrillary tangles. AD is also accompanied by an extensive functional deficit in the cholinergic system, involving the neuronal-type nicotinic acetylcholine receptor (AChR). Furthermore there is increasing evidence showing a misregulation of cholesterol metabolism in the development of the disease. Since cholesterol affects AChR protein at multiple levels, the cognitive impairment and other neurological correlates of AD might be partly associated with an abnormal crosstalk between the receptor protein and the sterol in this synaptopathy. Copyright 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914249     DOI: 10.1016/j.febslet.2009.11.036

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  The α7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane.

Authors:  José O Colón-Sáez; Jerrel L Yakel
Journal:  J Physiol       Date:  2011-05-03       Impact factor: 5.182

Review 2.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

3.  Scutellarin protects against Aβ-induced learning and memory deficits in rats: involvement of nicotinic acetylcholine receptors and cholinesterase.

Authors:  Li-li Guo; Zhi-zhong Guan; Yong-lin Wang
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

4.  Cerebrovascular Gi Proteins Protect Against Brain Hypoperfusion and Collateral Failure in Cerebral Ischemia.

Authors:  Salvador Castaneda-Vega; Sandra Beer-Hammer; Veronika Leiss; Hanna Napieczyńska; Marta Vuozzo; Andreas M Schmid; Hang Zeng; Yi He; Ursula Kohlhofer; Irene Gonzalez-Menendez; Leticia Quintanilla-Martinez; Johann-Martin Hempel; Maik Gollasch; Xin Yu; Bernd J Pichler; Bernd Nürnberg
Journal:  Mol Imaging Biol       Date:  2022-09-08       Impact factor: 3.484

Review 5.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Heterogeneous Inhibition in Macroscopic Current Responses of Four Nicotinic Acetylcholine Receptor Subtypes by Cholesterol Enrichment.

Authors:  Carlos A Báez-Pagán; Natalie Del Hoyo-Rivera; Orestes Quesada; José David Otero-Cruz; José A Lasalde-Dominicci
Journal:  J Membr Biol       Date:  2016-04-26       Impact factor: 1.843

7.  Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor.

Authors:  Carlos J Baier; Jacques Fantini; Francisco J Barrantes
Journal:  Sci Rep       Date:  2011-08-19       Impact factor: 4.379

8.  Design of new α-conotoxins: from computer modeling to synthesis of potent cholinergic compounds.

Authors:  Igor E Kasheverov; Maxim N Zhmak; Alexey Y Khruschov; Victor I Tsetlin
Journal:  Mar Drugs       Date:  2011-09-28       Impact factor: 6.085

9.  Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling.

Authors:  David A Hicks; Natalia N Nalivaeva; Anthony J Turner
Journal:  Front Physiol       Date:  2012-06-22       Impact factor: 4.566

10.  How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains.

Authors:  Jacques Fantini; Francisco J Barrantes
Journal:  Front Physiol       Date:  2013-02-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.